{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:16:00Z","timestamp":1778732160900,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22J23272"],"award-info":[{"award-number":["JP22J23272"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K23434"],"award-info":[{"award-number":["JP24K23434"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ae0121010"],"award-info":[{"award-number":["JP25ae0121010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ae0121010"],"award-info":[{"award-number":["JP24ae0121010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ae0121010"],"award-info":[{"award-number":["JP22ae0121010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ae0121010"],"award-info":[{"award-number":["JP23ae0121010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114293","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T22:11:43Z","timestamp":1759702303000},"page":"114293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Control of pharmacokinetics of radioimmunoconjugates using chelating agents containing poly(ethylene glycol)"],"prefix":"10.1016","volume":"388","author":[{"given":"Kazuma","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Jinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Shimohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114293_bb0005","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1021\/acs.molpharmaceut.2c00563","article-title":"Immuno-PET imaging and radioimmunotherapy of lymphomas","volume":"19","author":"Lee","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114293_bb0010","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/cancers14061454","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"14","author":"Parakh","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.114293_bb0015","first-page":"165","article-title":"Advances in antibody-based therapy in oncology","volume":"4","author":"Zinn","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2025.114293_bb0020","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","article-title":"Receptor-ligand interactions for optimized endocytosis in targeted therapies","volume":"380","author":"Sung","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114293_bb0025","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/acs.bioconjchem.3c00374","article-title":"The evolving landscape of antibody-drug conjugates: in depth analysis of recent research progress","volume":"34","author":"Sasso","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0030","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2025.114293_bb0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114293_bb0040","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1021\/acs.jmedchem.2c00339","article-title":"Antibody-drug conjugates for immunology","volume":"65","author":"Dragovich","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116709","article-title":"Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads","volume":"276","author":"Xi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0050","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114293_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: Trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nucmedbio.2015.07.012","article-title":"Development of [64Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging","volume":"43","author":"Alirezapour","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2025.114293_bb0065","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted therapy with immunoconjugates for multiple myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114293_bb0070","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/pharmaceutics14122824","article-title":"Engineering of a fully human anti-MUC-16 antibody and evaluation as a PET imaging agent","volume":"14","author":"Babeker","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114293_bb0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/ph15050570","article-title":"Carbonic anhydrase IX-targeted alpha-radionuclide therapy with 225Ac inhibits tumor growth in a renal cell carcinoma model","volume":"15","author":"Merkx","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2025.114293_bb0080","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","article-title":"Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114293_bb0085","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1039\/D3SC06365H","article-title":"Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX","volume":"15","author":"Morgan","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2025.114293_bb0090","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00259-024-06648-3","article-title":"Effectiveness of [67Cu]cu-trastuzumab as a theranostic against HER2-positive breast cancer","volume":"51","author":"Pougoue Ketchemen","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114293_bb0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2016.02.008","article-title":"Role of antibodies in diagnosis and treatment of ovarian cancer: basic approach and clinical status","volume":"226","author":"Bhatt","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114293_bb0100","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.114293_bb0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cpt.2598","article-title":"Clinical pharmacology of radiotheranostics in oncology","volume":"113","author":"Te Beek","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114293_bb0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7150\/thno.37098","article-title":"ImmunoPET predicts response to met-targeted radioligand therapy in models of pancreatic cancer resistant to met kinase inhibitors","volume":"10","author":"Escorcia","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114293_bb0115","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.7150\/thno.38236","article-title":"Preclinical evaluation of an 111In\/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer","volume":"10","author":"Kelly","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114293_bb0120","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.7150\/thno.57177","article-title":"Perspectives on metals-based radioimmunotherapy (RIT): moving forward","volume":"11","author":"White","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114293_bb0125","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: concept, design, and applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.114293_bb0130","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1021\/acs.jmedchem.3c00753","article-title":"Site-specific conjugation of 6 DOTA chelators to a CA19-9-targeting scFv-Fc antibody for imaging and therapy","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0135","first-page":"435","article-title":"Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy","volume":"17","author":"O'Donoghue","year":"2002","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.jconrel.2025.114293_bb0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.114293_bb0145","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.3390\/cancers13215570","article-title":"Radioimmunotherapy in oncology: overview of the last decade clinical trials","volume":"13","author":"Rondon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.114293_bb0150","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/1078-0432.CCR-17-0310","article-title":"131I-labeled anti-HER2 camelid sdAb as a theranostic tool in cancer treatment","volume":"23","author":"D'Huyvetter","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114293_bb0155","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/pharmaceutics15030719","article-title":"\"click-to-clear\": a strategy to minimize radioactivity from the blood pool utilizing staudinger ligation","volume":"15","author":"Soni","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114293_bb0160","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.7150\/thno.84865","article-title":"Click-to-release: cleavable radioimmunoimaging with [89Zr]Zr-DFO-trans-cyclooctene-trastuzumab increases tumor-to-blood ratio","volume":"13","author":"Vlastara","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.114293_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.047","article-title":"Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy","volume":"381","author":"Altai","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114293_bb0170","doi-asserted-by":"crossref","first-page":"12812","DOI":"10.1021\/acs.jmedchem.3c00472","article-title":"Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates","volume":"66","author":"Nakashima","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0175","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1016\/j.bmc.2012.10.025","article-title":"SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies","volume":"20","author":"Vaidyanathan","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0180","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.3390\/molecules24213907","article-title":"Observations on the effects of residualization and dehalogenation on the utility of N-Succinimidyl Ester acylation agents for radioiodination of the internalizing antibody Trastuzumab","volume":"24","author":"Chitneni","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2025.114293_bb0185","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0969-8043(02)00167-7","article-title":"Design and synthesis of 225Ac radioimmunopharmaceuticals","volume":"57","author":"McDevitt","year":"2002","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.jconrel.2025.114293_bb0190","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1039\/c3cc38507h","article-title":"The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging","volume":"49","author":"Stasiuk","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2025.114293_bb0195","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2025.114293_bb0200","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1039\/C6SC04128K","article-title":"Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development","volume":"8","author":"Pandya","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2025.114293_bb0205","doi-asserted-by":"crossref","first-page":"13429","DOI":"10.1021\/acs.jmedchem.1c00772","article-title":"Radiotheranostics using a novel 225Ac-labeled radioligand with improved pharmacokinetics targeting prostate-specific membrane antigen","volume":"64","author":"Iikuni","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114293_bb0210","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1039\/c3sc50903f","article-title":"Responsive MR-imaging probes for N-methyl-D-aspartate receptors and direct visualisation of the cell-surface receptors by optical microscopy","volume":"4","author":"Sim","year":"2013","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2025.114293_bb0215","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1002\/anie.201704773","article-title":"Molecular magnetic resonance imaging of lung fibrogenesis with an oxyamine-based probe","volume":"56","author":"Waghorn","year":"2017","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.114293_bb0220","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0960-894X(00)00413-3","article-title":"A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling","volume":"10","author":"Eisenwiener","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2025.114293_bb0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2025.114293_bb0230","first-page":"850","article-title":"Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2","volume":"36","author":"Anderson","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114293_bb0235","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/MNM.0b013e328354df7c","article-title":"Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts","volume":"33","author":"Abbas","year":"2012","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.jconrel.2025.114293_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.bjp.0705915","article-title":"Preclinical characterisation of 111In-DTPA-trastuzumab","volume":"143","author":"Lub-de Hooge","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114293_bb0245","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","article-title":"Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors","volume":"71","author":"Rudnick","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114293_bb0250","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2967\/jnumed.108.060392","article-title":"Development and characterization of clinical-grade 89Zr-trastuzumab for HER2\/neu immunoPET imaging","volume":"50","author":"Dijkers","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114293_bb0255","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00259-016-3499-x","article-title":"Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET","volume":"44","author":"Vugts","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.114293_bb0260","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2967\/jnumed.118.223636","article-title":"The impact of Fc\u03b3RI binding on immuno-PET","volume":"60","author":"Vivier","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.114293_bb0265","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11307-023-01818-5","article-title":"Site-specific photoaffinity bioconjugation for the creation of 89Zr-labeled radioimmunoconjugates","volume":"25","author":"Delaney","year":"2023","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.jconrel.2025.114293_bb0270","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114293_bb0275","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2024.08.049","article-title":"Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates","volume":"375","author":"Tedeschini","year":"2024","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500906X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500906X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:43:37Z","timestamp":1778730217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592500906X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"alternative-id":["S016836592500906X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114293","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Control of pharmacokinetics of radioimmunoconjugates using chelating agents containing poly(ethylene glycol)","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114293"}}